BioLineRx (BLRX) Competitors

$3.06 -0.07 (-2.24%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$3.06 0.00 (0.00%)

As of 05/14/2026 04:10 PM Eastern

BLRX vs. ESLA, MGX, OKUR, ZYBT, and ELUT

Should you buy BioLineRx stock or one of its competitors? MarketBeat compares BioLineRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLineRx include Estrella Immunopharma (ESLA), Metagenomi (MGX), OnKure Therapeutics (OKUR), Zhengye Biotechnology (ZYBT), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry.

How does BioLineRx compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 563.90%. Given Estrella Immunopharma's higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

BioLineRx has higher revenue and earnings than Estrella Immunopharma. BioLineRx is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.35	N/A
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Estrella Immunopharma and 2 mentions for BioLineRx. Estrella Immunopharma's average media sentiment score of 0.96 beat BioLineRx's score of 0.93 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Estrella Immunopharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Estrella Immunopharma has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. Estrella Immunopharma's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-430.91%
BioLineRx	-99.58%	-5.61%	-2.81%

Summary

BioLineRx beats Estrella Immunopharma on 8 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Metagenomi?

BioLineRx (NASDAQ:BLRX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

BioLineRx has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, Metagenomi had 8 more articles in the media than BioLineRx. MarketBeat recorded 10 mentions for Metagenomi and 2 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.93 beat Metagenomi's score of -0.17 indicating that BioLineRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 17.8% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Metagenomi has a consensus price target of $9.00, suggesting a potential upside of 566.67%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

BioLineRx has higher earnings, but lower revenue than Metagenomi. BioLineRx is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A
Metagenomi	$25.21M	2.02	-$87.87M	-$2.30	N/A

BioLineRx has a net margin of -99.58% compared to Metagenomi's net margin of -384.61%. BioLineRx's return on equity of -5.61% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
Metagenomi	-384.61%	-51.23%	-36.62%

Summary

BioLineRx beats Metagenomi on 9 of the 16 factors compared between the two stocks.

How does BioLineRx compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

OnKure Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

In the previous week, OnKure Therapeutics had 5 more articles in the media than BioLineRx. MarketBeat recorded 7 mentions for OnKure Therapeutics and 2 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.93 beat OnKure Therapeutics' score of -0.21 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OnKure Therapeutics currently has a consensus price target of $27.00, indicating a potential upside of 708.38%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

BioLineRx has higher revenue and earnings than OnKure Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A

OnKure Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. BioLineRx's return on equity of -5.61% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
BioLineRx	-99.58%	-5.61%	-2.81%

Summary

BioLineRx beats OnKure Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Zhengye Biotechnology?

BioLineRx (NASDAQ:BLRX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, BioLineRx and BioLineRx both had 2 articles in the media. Zhengye Biotechnology's average media sentiment score of 1.44 beat BioLineRx's score of 0.93 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
Zhengye Biotechnology	Positive

BioLineRx has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, meaning that its share price is 347% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A
Zhengye Biotechnology	$16.64M	2.71	-$9.98M	N/A	N/A

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. Zhengye Biotechnology's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

BioLineRx beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Elutia?

BioLineRx (NASDAQ:BLRX) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

BioLineRx has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Elutia has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Elutia has a net margin of 282.63% compared to BioLineRx's net margin of -99.58%. Elutia's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
Elutia	282.63%	N/A	-49.57%

In the previous week, Elutia had 4 more articles in the media than BioLineRx. MarketBeat recorded 6 mentions for Elutia and 2 mentions for BioLineRx. Elutia's average media sentiment score of 1.24 beat BioLineRx's score of 0.93 indicating that Elutia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elutia has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A
Elutia	$12.29M	3.62	$53.38M	$0.82	1.27

Elutia has a consensus price target of $6.00, indicating a potential upside of 476.92%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Elutia beats BioLineRx on 11 of the 16 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.62M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-18.00	18.70	20.66	25.63
Price / Sales	11.28	271.92	549.87	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	0.57	4.42	9.93	6.97
Net Income	-$1.17M	$72.19M	$3.55B	$333.62M
7 Day Performance	-0.33%	-0.43%	1.71%	1.09%
1 Month Performance	28.57%	-0.96%	0.49%	3.08%
1 Year Performance	-0.97%	45.81%	39.41%	35.68%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	1.0802 of 5 stars	$3.06 -2.2%	N/A	-1.0%	$13.62M	$1.18M	N/A	40
ESLA Estrella Immunopharma	3.0623 of 5 stars	$1.24 -2.0%	$8.00 +547.8%	+21.7%	$52.70M	N/A	N/A	N/A	Short Interest Decrease Gap Down
MGX Metagenomi	2.8465 of 5 stars	$1.36 +0.4%	$9.00 +564.2%	-10.0%	$51.02M	$25.21M	N/A	236	News Coverage Earnings Report Analyst Forecast Gap Down
OKUR OnKure Therapeutics	3.0256 of 5 stars	$3.42 -0.6%	$27.00 +689.7%	+82.5%	$46.68M	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	1.0919 of 5 stars	$0.99 -1.2%	N/A	-88.7%	$46.68M	$16.64M	N/A	278	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. ESLA, MGX, OKUR, ZYBT, and ELUT

How does BioLineRx compare to Estrella Immunopharma?

Summary

How does BioLineRx compare to Metagenomi?

Summary

How does BioLineRx compare to OnKure Therapeutics?

Summary

How does BioLineRx compare to Zhengye Biotechnology?

Summary

How does BioLineRx compare to Elutia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. ESLA, MGX, OKUR, ZYBT, and ELUT

How does BioLineRx compare to Estrella Immunopharma?

Do analysts prefer ESLA or BLRX?

Which has stronger valuation & earnings, ESLA or BLRX?

Does the media favor ESLA or BLRX?

Do insiders and institutionals hold more shares of ESLA or BLRX?

Which has more volatility and risk, ESLA or BLRX?

Is ESLA or BLRX more profitable?

Summary

How does BioLineRx compare to Metagenomi?

Which has more volatility & risk, BLRX or MGX?

Does the media prefer BLRX or MGX?

Do institutionals & insiders believe in BLRX or MGX?

Do analysts recommend BLRX or MGX?

Which has stronger earnings and valuation, BLRX or MGX?

Is BLRX or MGX more profitable?

Summary

How does BioLineRx compare to OnKure Therapeutics?

Which has more risk & volatility, OKUR or BLRX?

Does the media favor OKUR or BLRX?

Do insiders and institutionals believe in OKUR or BLRX?

Do analysts recommend OKUR or BLRX?

Which has higher earnings & valuation, OKUR or BLRX?

Is OKUR or BLRX more profitable?

Summary

How does BioLineRx compare to Zhengye Biotechnology?

Does the media refer more to BLRX or ZYBT?

Which has more risk & volatility, BLRX or ZYBT?

Do analysts rate BLRX or ZYBT?

Which has better valuation & earnings, BLRX or ZYBT?

Do institutionals and insiders believe in BLRX or ZYBT?

Is BLRX or ZYBT more profitable?

Summary

How does BioLineRx compare to Elutia?

Which has more risk and volatility, BLRX or ELUT?

Is BLRX or ELUT more profitable?

Does the media prefer BLRX or ELUT?

Do insiders & institutionals have more ownership in BLRX or ELUT?

Which has higher earnings and valuation, BLRX or ELUT?

Do analysts recommend BLRX or ELUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools